Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors by Kunzmann, A.T. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1053/j.gastro.2018.09.038
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Kunzmann, A. T., Canadas Garre, M., Thrift, A. P., McMenamin, Ú. C., Johnston, B. T., Cardwell, C. R., ...
Coleman, H. G. (2018). Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of
Esophageal Adenocarcinoma Compared to Clinical Risk Factors. Gastroenterology.
https://doi.org/10.1053/j.gastro.2018.09.038
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
Accepted Manuscript
Information on Genetic Variants Does Not Increase Identification of Individuals at
Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors
A.T. Kunzmann, M. Canadas Garre, A.P. Thrift, Ú.C. McMenamin, B.T. Johnston,
C.R. Cardwell, L.A. Anderson, A.D. Spence, J. Lagergren, S.-H. Xie, L.J. Smyth,
A.J. McKnight, H.G. Coleman
PII: S0016-5085(18)35032-7
DOI: 10.1053/j.gastro.2018.09.038
Reference: YGAST 62148
To appear in: Gastroenterology
Accepted Date: 13 September 2018
Please cite this article as: Kunzmann A, Canadas Garre M, Thrift A, McMenamin Ú, Johnston
B, Cardwell C, Anderson L, Spence A, Lagergren J, Xie S-H, Smyth L, McKnight A, Coleman
H, Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of
Esophageal Adenocarcinoma Compared to Clinical Risk Factors, Gastroenterology (2018), doi: https://
doi.org/10.1053/j.gastro.2018.09.038.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Title: Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of 
Esophageal Adenocarcinoma Compared to Clinical Risk Factors 
Authors: 
AT Kunzmann1, M Canadas Garre2, AP Thrift3, ÚC McMenamin1, BT Johnston4 CR Cardwell1, LA 
Anderson1, AD Spence1, J Lagergren5,6, S-H Xie5, LJ Smyth2, AJ McKnight2 & HG Coleman1,7 
Authors’ affiliations: 
1 Cancer Epidemiology Research Group, Centre for Public Health, Queen’s University Belfast, Belfast, 
Northern Ireland, United Kingdom 
2 Epidemiology and Public Health Research Group, Centre for Public Health, Queen’s University 
Belfast, Belfast, Northern Ireland, United Kingdom 
3 Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of 
Medicine, Houston, Texas 
4 Royal Victoria Hospital, Belfast Health & Social Care Trust, Belfast, N. Ireland, United Kingdom 
5 Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska 
Institutet, Karolinska University Hospital, Stockholm, Sweden 
6 School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom 
7 Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland, 
United Kingdom 
Corresponding author: Dr Andrew Kunzmann. Mailing address: Centre for Public Health, Queen’s 
University Belfast, Institute of Clinical Sciences-B, Royal Victoria Hospital Site, Grosvenor Rd, Belfast, 
Northern Ireland, BT12 6BJ. E-mail: a.kunzmann@qub.ac.uk. 
Grant support: The project was kindly funded by Ochre charity (Registered charity number: 
SC032343). MCG is funded by a Science Foundation Ireland-Department for the Economy (SFI-DfE) 
Investigator Program Partnership Award (15/IA/3152). 
Disclosures: The authors disclose no potential conflicts of interest. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Author contributions:  
ATK: study concept and design; acquisition of data; analysis and interpretation of data; drafting of 
the manuscript; critical revision of the manuscript for important intellectual content; statistical 
analysis; obtained funding. 
MCG: acquisition of data; analysis and interpretation of data; statistical analysis; critical revision of 
the manuscript for important intellectual content. 
APT: critical revision of the manuscript for important intellectual content. 
ÚCM: acquisition of data; critical revision of the manuscript for important intellectual content. 
BTJ: critical revision of the manuscript for important intellectual content. 
CRC: acquisition of data; analysis and interpretation of data; critical revision of the manuscript for 
important intellectual content. 
LAA: critical revision of the manuscript for important intellectual content. 
ADS: critical revision of the manuscript for important intellectual content. 
JL: critical revision of the manuscript for important intellectual content. 
SX: critical revision of the manuscript for important intellectual content. 
LJS: critical revision of the manuscript for important intellectual content. 
AJM: critical revision of the manuscript for important intellectual content. 
HGC: study concept and design; acquisition of data; critical revision of the manuscript for important 
intellectual content; study supervision. 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Abstract 
We previously developed a tool that identified individuals who later developed esophageal 
adenocarcinoma (EAC; based on age, sex, body mass index, smoking status, and prior esophageal 
conditions) with an area under the curve of 0.80. In this study, we collected data from 329,463 
individuals in the UK Biobank cohort who were tested for genetic susceptibility to EAC (a polygenic 
risk score based on 18 recognized genetic variants). We found that after inclusion of this genetic 
information, the area under the curve for identification of individuals who developed EAC remained 
at 0.80. Testing for genetic variants associated with EAC therefore seems unlikely to improve 
identification of individuals at risk of EAC.  
Keywords: esophagus; cancer; early detection; stratification; mutation 
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Novel screening and risk-stratification methods are needed to improve early detection of esophageal 
adenocarcinoma as the vast majority of patients are currently diagnosed at a late stage when 
survival is poor1 and population-wide endoscopy screening is unlikely to be cost-effective2. 
Established clinical risk factors may be useful in identifying individuals at a higher risk of esophageal 
adenocarcinoma4-6. Our findings within the UK Biobank indicated that a model including age, sex, 
body mass index (BMI), smoking status and prior esophageal conditions had an area under receiver 
operating characteristic curve (AUROC) for predicting esophageal adenocarcinoma within 5 years of 
0.80 (95% CI 0.76-0.82)3. Whilst these results suggested that clinical risk factors may be useful as an 
inexpensive and non-invasive risk-stratification tool, additional robust, minimally-invasive follow-up 
risk-stratification methods will likely be required to identify individuals at sufficiently high risk to 
warrant endoscopy screening.  Conversely, those at lowest risk could avoid unnecessary and invasive 
procedures. 
Germline mutations associated with esophageal adenocarcinoma risk can be readily assessed using 
DNA derived from minimally invasively biological samples, thus their evaluation for the purpose of 
risk stratification in a routine setting is appealing. The clinical utility of assessing single nucleotide 
polymorphisms (SNPs) for esophageal adenocarcinoma risk-prediction has been investigated in a 
previous case-control study consortium6, but remains to be investigated in large-scale prospective 
studies. 
In this study, we analyzed prospective data from the UK Biobank to assess whether the addition of 
genetic factors to an established clinical risk prediction score enhances the ability to identify 
individuals at high risk of esophageal adenocarcinoma development within 5 years. A secondary aim 
was to validate the associations between SNPs and esophageal adenocarcinoma development 
identified in large genome-wide association studies (GWAS) 7-8.  
Clinical factors were assessed using a touchscreen questionnaire, and BMI measurements and blood 
tests were taken at baseline9 . The clinical risk-factors (age ,sex, BMI, smoking status and reflux 
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diagnosis/symptoms) used for risk-prediction modelling were selected from a previous investigation 
within the UK Biobank3. Germline mutations were genotyped using the Affymetrix UK BiLEVE and UK 
Biobank Axiom arrays (Santa Clara, CA, USA), followed by imputation methods to >90 million 
variants. Previous GWAS identified 24 genetic variants associated with esophageal adenocarcinoma7-
9. Two SNPs were unavailable for analysis (rs9918259 and rs75783973), two SNPs were excluded due 
to linkage disequilibrium (Supplementary Table 1) and one SNP (rs9257809) was excluded as it was 
not in Hardy-Weinberg equilibrium (P<0.01). Polygenic risk scores were calculated by summing the 
positive risk allele counts for 18 genetic variants weighted by their odds ratios from previous GWAS 
8-9, and dividing the total by 186.  
Diagnostic accuracy was quantified for the combined genetic and clinical risk factor models using the 
AUROC curve with 95% confidence interval (CI). A points-based model, created from our previous 
investigation of established clinical risk factors3, was used to assign points to tertiles of the polygenic 
risk score. Sensitivity, specificity, Youden’s index (sensitivity + specificity -1) and net reclassification 
index10 were assessed for individuals above each points based cut-off threshold when using the 
established risk factor model alone and when combined with the genetic factors. Further details are 
outlined in the Supplementary Methods.  
Of 502,640 participants in UK Biobank, the following exclusions were applied: 117,891 were aged 
under 50 years, 30,665 had a history of cancer (or cancer within 6 months of baseline), 8,515 had 
missing clinical or genetic data, two participants withdrew consent, 772 had insufficient genetic data 
quality and 15,152 reported a non-White ethnicity. A total of 329,643 (65.6%) were eligible for 
inclusion, among whom 214 individuals were diagnosed with esophageal adenocarcinoma within 5 
years. Individuals diagnosed with esophageal adenocarcinoma were more likely to be older, male, 
smoke (current or former), have a higher BMI, have an existing esophageal condition, and have a 
higher polygenic risk score than non-cases (Supplementary Table 2). Mean follow-up time was 4.8 
(standard deviation 0.6) years. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
The strength of associations for each individual SNP were broadly in line with expectations 7-9, 
though modest and not statistically significant, in either crude or multivariable analyses 
(Supplementary Table 3). The strongest adjusted associations with esophageal adenocarcinoma 
within 5 years were for SNPs at, or near, the genes CFTR (rs17451754; OR 1.21, 95% CI 0.80-1.83) 
and BARX1 (rs11789015; OR 1.20, 95% CI 0.96-1.50).  
The association between polygenic risk score and risk of esophageal adenocarcinoma within 5 years 
was modest and not statistically significant (Adjusted OR middle versus bottom tertile 1.09, 95% CI 0.77-1.55; 
Adjusted OR top versus bottom tertile 1.38, 95% CI 0.99-1.92). 
The AUROC for the clinical risk factor model was 0.80 (95% CI 0.76-0.82), as previously published3, 
and was unchanged when polygenic risk score categories were added to the model (0.80, 95% CI 
0.77-0.83) (Figure 1) and in a secondary analyses adding the 18 SNPs to the model (0.81, 95% CI 
0.78-0.83). 
A points-based model, used points created from a previous investigation of established clinical risk 
factors3, i.e. age (55-60 years: 1.5; 60-65 years: 2.5; 65+ years: 3.5), sex (males: 4), smoking status 
(former: 2; current: 3.5), BMI (>25-30: 1; 30-<35: 1.5; 35+: 2.5), history of esophageal conditions or 
treatment (1.5). Points for polygenic risk score categories were assigned (middle category=0 points, 
top category=1 point) by dividing their coefficient when added to the clinical risk factor model by the 
smallest coefficient in the previous model (0.40 for BMI of 25-<30 kg/m2) and rounding to the 
nearest 0.5 to allow easier to interpret cut-offs. When comparing the combined clinical and 
polygenic risk score model to the original clinical points based model, changes in net reclassification 
index10 and Youden’s index11 were modest at any of the cut-off points, as modest improvements in 
sensitivity were offset by modest reductions in specificity (Table 1). 
The results from this large UK cohort study with prospective follow-up data suggest that SNPs 
previously implicated in esophageal adenocarcinoma susceptibility do not aid risk-prediction alone, 
or in conjunction with known clinical risk factors. The lack of predictive ability occurred regardless of 
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method used to derive the polygenic risk score and seems unlikely to be improved by additional 
statistical power as AUROC confidence intervals were narrow. These results validate findings from a 
previous case-control study6, despite the weaker association between polygenic risk scores and 
oesophageal adenocarcinoma in the current study. Similar lack of improvements were apparent 
when stratified by certain demographic features (Supplementary Table 4). Future genetic analyses of 
families with a history of esophageal adenocarcinoma may be required to identify a polygenic risk 
score that accounts for a larger proportion of the heritability of esophageal adenocarcinoma than 
the SNPs identified using GWAS studies to date.  
Nevertheless, the results provide modest support for a potential role of some genes in esophageal 
adenocarcinoma development. In particular, genetic variants on or near the CFTR gene (rs17451754) 
related to cystic fibrosis, which displays phenotypic overlap with reflux12, and the BARX1 gene 
(rs11789015) related to differentiation of esophageal epithelia13.  
To our knowledge, this is the first prospective assessment of genetic susceptibility combined with 
known clinical risk factors in esophageal adenocarcinoma risk prediction. Potential limitations 
include reduced statistical power to detect significant associations for low frequency SNPs; lack of 
information for two SNPs previously identified in GWAS or family history of esophageal 
adenocarcinoma and; criticism of the UK Biobank’s generalizability14.  
Thus, testing for currently recognized germline mutations is unlikely to improve stratification of 
individuals at risk of esophageal adenocarcinoma at a population level. Future studies should 
examine other novel screening methods, biomarkers, or epigenetic studies to achieve earlier 
detection of this tumor.  
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Figure legend 
Figure 1. Receiver operating characteristic curve for the clinical model alone (•) and when 
combined with polygenic risk score categories (+) for predicting risk of esophageal 
adenocarcinoma within 5 years.  
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Table 1. Performance statistics of the combined (clinical and polygenic risk scores) and clinical 
only points-based esophageal adenocarcinoma risk-prediction models at different points based 
cut-offs 
Points cut-off   Patients deemed high-risk (%) Sensitivity  Specificity  
Youden’s 
index NRI
1
 
7+ 
Combined 146,042 (44.3%) 86.4% 55.7% 0.42 -0.04 
Original 134,550 (40.8%) 85.0% 59.2% 0.44 - 
       
8+ 
Combined 110,358 (33.5%) 81.3% 66.5% 0.48 0.01 
Original 98,203 (29.8%) 77.1% 70.2% 0.47 - 
       
9+ 
Combined 78,215 (23.7%) 69.2% 76.3% 0.46 0.05 
Original 68,383 (20.8%) 63.6% 79.2% 0.43 - 
       
10+ 
Combined 52,439 (15.9%) 57.9% 84.1% 0.42 0.07 
Original 44,350 (13.5%) 51.9% 86.5% 0.38 - 
1
 Net Reclassification index: positive values indicate that a larger proportion of individuals with events were moved up to the 
high-risk group than individuals without events when changing from the original to combined model. 
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Supplementary methods 
Study design 
This cohort study used prospective data from the UK Biobank, which recruited 502,640 men and 
women aged 40-69 years from one of 22 centers located across England, Scotland, and Wales 
between 2006 and 2010
9
. Approximately 9.2 million individuals registered with the National Health 
Service living within a 25-mile (~40km) radius of one of the 22 centers were invited to participate. 
The response rate was 5.5% (n=503,325)
14
. Included in the present study were individuals reporting 
a white ethnicity who had not withdrawn consent, aged ≥50 years (as upper gastrointestinal cancers 
are rare aged <50), without a history of cancer (excluding non-melanoma skin cancer) at or before 
baseline or within 6 months following baseline (to exclude diagnostic delays), and with complete 
information on relevant risk factors and SNPs.  
The UK Biobank was approved by the North West Multi-Centre Research Ethics Committee, and all 
participants provided written informed consent.  
Assessment and classification of clinical and genetic risk-factors 
Participants were asked to complete electronic touchscreen questionnaires at baseline, which 
enquired about a wide range of potential risk factors for chronic diseases (including age, sex, 
smoking status and prior medical conditions); have anthropometric measurements taken and; 
provide a blood test for genetic analysis at baseline.  
UK Biobank samples were genotyped using the Affymetrix UK Biobank Axiom array (Santa Clara, CA, 
USA) or the similar Affymetrix UK BiLEVE Axiom array (the former is an update of latter, and the two 
arrays share 95% content). Quality control, phasing and imputation through the IMPUTE3 program 
were carried out centrally.   
Hardy-Weinberg equilibrium and pairwise haplotype frequencies were estimated, and Lewontin’s D 
prime (D′) and the linkage disequilibrium coefficient (r
2
) were calculated.  
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Previous genome-wide association studies (GWAS) identified 24 genetic variants associated with 
esophageal adenocarcinoma
7-9
. Two of these genetic variants (rs9918259 and rs75783973) identified 
in previous GWAS
7-8
 were not imputed so were unavailable for this analysis. Two further SNPs were 
excluded due to linkage disequilibrium with other SNPs in the analysis (rs76014404, R
2
=0.96 and 
rs199620551, R
2
=0.77, Supplementary Table 1) and one SNP (rs9257809) was excluded as it was not 
in Hardy-Weinberg equilibrium (P<0.01). Polygenic risk scores were calculated by summing the 
positive risk allele counts for the 18 variants weighted by their odds ratios for associations with 
esophageal adenocarcinoma from previous GWAS
7-9
, and dividing the total by 18. The polygenic risk 
score categories were created using tertiles.  
Outcome assessment  
The UK Biobank is regularly linked to UK cancer registry data from the Health and Social Care 
Information Centre (in England and Wales), the Scottish Cancer Registry (in Scotland) and death 
records from the UK Office of National Statistics (ONS). Cancer data were provided up until 30
th
 
September 2014. Newly diagnosed cancers were classified by site according to International 
Classification of Diseases, 10
th
 version (ICD/10) and histology (ICD-O morphology codes). Primary 
esophageal adenocarcinoma (ICD/10 C15, with ICD-O 8140–8573) diagnosed between 6 months 
(due to potential diagnostic delays) and 5 years from baseline was the main outcome of interest. The 
5-year follow-up may have reduced statistical power but may offer a more clinically useful time-
point to initiate screening. 
Statistical analysis 
Logistic regression was used to assess the association between established clinical risk factors alone, 
and in combination with polygenic risk score categories, and risk of esophageal adenocarcinoma 
within 5 years. Diagnostic accuracy was quantified for the clinical factor and combined genetic and 
factor models using the AUROC curve with 95% confidence interval (CI).  
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A points-based model, created from a previous investigation of established clinical risk factors 
3
, was 
used to assign points to tertiles of the polygenic risk score by dividing by the smallest coefficient in 
the previous model (0.40 for BMI of 25-<30kg/m
2
) and rounding to the nearest 0.5 to allow ease of 
calculation without a computer and easier to interpret cut-offs. Sensitivity, specificity, Youden’s 
index (sensitivity + specificity -1) and net reclassification index
10
 were assessed for individuals above 
each points based cut-off threshold when using the established risk factor model alone and when 
combined with the genetic factors. 
Logistic regression was used to assess the association between individual SNPs and risk of 
esophageal adenocarcinoma within 5 years, with and without inclusion of established clinical risk 
factors or other SNPs. Diagnostic accuracy was quantified for the model including all 18 SNPs and 
clinical risk factors model using the AUROC curve with 95% confidence interval (CI).  
Stratified analyses by age, sex, BMI, smoking history and prior esophageal conditions were 
conducted to assess whether the change in diagnostic accuracy when adding the polygenic risk 
scores to the established clinical factors was improved in certain high risk groups. 
SNPs were extracted and linkage disequilibrium, Hardy-Weinberg equilibrium and minor allele 
frequencies were calculated using PLINK 
15
.  All other analyses were conducted using Stata/SE 
statistical software (version 14.1, College Station, TX, USA). 
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Supplementary Table 1. Linkage disequilibrium 
Chr GENE SNP1 SNP2 R2 D’ 
2 GDF7& SATB2 rs7255 rs13397172 <0.01 <0.01 
2 SATB2 & GDF7 rs13397172 rs3072 <0.01 <0.01 
2 GDF7 rs7255 rs3072 0.63 0.97 
3 FOXP1 & HTR3C rs2687202 rs9823696 <0.01 0.02 
6 KHDRBS2-MTRNR2L9 
& MHC region 
rs62423175 rs9257809 <0.01 0.01 
6 MHC region & 
KHDRBS2 
rs9257809 6:62391538_TAAACA_T <0.01 <0.01 
6 KHDRBS2 rs62423175 6:62391538_TAAACA_T <0.01 0.94 
7 CFTR & ASZ1 rs17451754 rs2188554 0.48 0.85 
8 LINC00208-BLK & 
MSRA 
rs10108511 rs17749155 0.11 0.71 
9 MSRA rs7852462 rs11789015 <0.01 <0.01 
15 ALDH1A2 rs2464469 15:58267416_GACAT_
G 
0.46 0.89 
19 CRTC1 19:18804294_TG_T rs10419226 0.96 0.99 
19 CRTC1 rs10419226 rs10423674 0.39 0.96 
19 CRTC1 19:18804294_TG_T rs10423674 0.42 0.98 
Abbreviations: Chr: Chromosome; SNP: Single Nucleotide Polymorphism; R
2
: linkage disequilibrium coefficient; D’: 
Lewontin’s D prime. 
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Supplementary Table 2. Characteristics of study population who did or did not develop esophageal 
adenocarcinoma within 5 years 
 
No esophageal 
adenocarcinoma 
Esophageal 
adenocarcinoma 
 
Number (%) Number (%) 
Total 329,429 214 
Age (years) 
  
50-<55 65,442 (19.9) 14 (6.5) 
55-<60 78,488 (23.8) 39 (18.2) 
60-<65 105,024 (31.9) 74 (34.6) 
65+ 80,475 (24.4) 87 (40.7) 
Sex 
  
Female 176,640 (53.6) 34 (15.9) 
Male 152,789 (46.4) 180 (84.1) 
Smoking status 
  
Never 172,236 (52.3) 55 (25.7) 
Former 125,886 (38.2) 114 (53.3) 
Current 31,307 (9.5) 45 (21.0) 
Body mass index 
  
<25 103,963 (31.6) 35 (16.4) 
25-<30 143,518 (43.6) 97 (45.3) 
30-<35 59,421 (18.0) 55 (25.7) 
35+ 22,527 (6.8) 27 (12.6) 
Esophageal condition1  
  
No 284,404 (86.3) 156 (72.9) 
Yes 45,025 (13.7) 58 (27.1) 
Polygenic risk score tertiles 
  
Low 109,820 (33.3) 61 (28.5) 
Medium 109,814 (33.3) 67 (31.3) 
High 109,795 (33.3) 86 (40.2) 
1 
Esophageal conditions included self-reported history of gastroesophageal reflux disease, Barrett’s esophagus, hiatus 
hernia or esophageal stricture and/or; esophageal fundoplication or hiatus hernia surgery and/or; anti-reflux medication 
use (none or any) 
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Supplementary Table 3. The association between individual SNPs (previously associated with 
esophageal adenocarcinoma or Barrett’s esophagus) and risk of esophageal adenocarcinoma within 
5 years in the UK Biobank.  
SNP Position: Gene Minor Allele Frequency 
Risk 
allele1 
Published 
OR/risk 
allele2 
Crude  
OR (95% CI) 
Multivariable3 
OR (95% CI) 
rs7255 2: 20878820 GDF7-LDAH 44% (T) T 1.17 1.18 (0.97-1.42) 1.17 (0.85-1.61) 
rs13397172 4 2: 200045039 SATB2 44% (T) C 1.13 1.04 (0.86-1.26) 1.05 (0.86-1.27) 
rs3072 2: 20878406 GDF7 36% (C) C 1.14 1.15 (0.94-1.39) 1.00 (0.73-1.39) 
rs2687202 3: 70929983 FOXP1 29% (T) T 1.13 1.08 (0.88-1.32) 1.07 (0.87-1.32) 
rs9823696 3: 183783353 HTR3C 38% (A) A 1.17 0.97 (0.80-1.18) 0.97 (0.79-1.18) 
rs62423175 6: 62195368 KHDRBS2-MTRNR2L9 17% (A) A 1.23 0.96 (0.74-1.25) 0.96 (0.74-1.25) 
rs17451754 7: 117256712 CFTR 13% (A) G 1.25 1.31 (0.96-1.78) 1.21 (0.80-1.83) 
rs2188554 7: 117040117 ASZ1 18% (G) A 1.23 1.23 (0.94-1.60) 1.10 (0.77-1.57) 
rs10108511 8: 11435516 LINC00208-BLK 46% (T) T 1.12 1.14 (0.94-1.38) 1.15 (0.94-1.40) 
rs17749155 8: 10068073 MSRA 16% (A) A 1.14 1.03 (0.79-1.33) 0.95 (0.73-1.26) 
rs7852462 9: 100310501 TMOD1 39% (T) C 1.08 1.15 (0.94-1.41) 1.15 (0.94-1.40) 
rs11789015 9: 96716028 BARX1 28% (G) A 1.20 1.22 (0.97-1.52) 1.20 (0.96-1.50) 
rs1247942 12: 114673723 LOC105369996-TBX5 41% (C) G 1.11 1.11 (0.91-1.35) 1.11 (0.91-1.35) 
rs2464469 15: 58362025 ALDH1A2 41% (G) G 1.11 1.08 (0.89-1.31) 1.15 (0.88-1.50) 
rs66725070 15: 58267416 ALDH1A2 46% (G) GACAT 1.15 1.00 (0.83-1.21) 0.90 (0.69-1.18) 
rs1979654 16: 86396835 LOC732275-FOXF1 41% (G) G 1.11 0.84 (0.69-1.03) 0.84 (0.69-1.02) 
rs10419226 19: 18803172 CRTC1 46% (T) T 1.18 0.93 (0.77-1.12) 0.85 (0.67-1.08) 
rs10423674 19: 18817903 CRTC1 33% (A) C 1.19 1.04 (0.85-1.28) 1.15 (0.89-1.48) 
1
 Allele associated with increased esophageal adenocarcinoma risk 
2
 Odds ratios for association with esophageal adenocarcinoma in previous GWAS and used in 
creation of polygenic risk scores in the current study.  
3
 Adjusted for age, sex, body mass index, smoking status and gastroesophageal reflux 
diagnosis/symptoms and other SNPs. 
4
 Formerly referred to as rs139606545 6 
Abbreviations: Chr: Chromosome; CI: Confidence interval; OR: Odds ratio; SNP: Single Nucleotide 
Polymorphism. 
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Supplementary Table 4. The diagnostic accuracy when using the original model alone and combined 
with the polygenic risk score in stratified analyses. 
 Original model 
AUC (95% CI) 
Original model + PRS 
AUC (95% CI) 
p-value for 
difference 
BMI    
Normal BMI 0.83 (0.76-0.89) 0.84 (0.78-0.90) 0.18 
Overweight or obese 0.78 (0.75-0.82) 0.79 (0.76-0.82) 0.37 
Smoking    
Never 0.78 (0.72-0.84) 0.78 (0.72-0.84) 0.26 
Ever 0.76 (0.73-0.79) 0.77 (0.73-0.80) 0.38 
Prior oesophageal condition    
No 0.80 (0.76-0.83) 0.80 (0.77-0.84) 0.14 
Yes 0.75 (0.69-0.81) 0.76 (0.70-0.81) 0.44 
Sex    
Men 0.73 (0.69-0.76) 0.73 (0.70-0.76) 0.15 
Women 0.71 (0.62-0.79) 0.71 (0.63-0.79) 0.82 
Age    
Under 60 0.83 (0.78-0.88) 0.84 (0.79-0.88) 0.16 
Over 60 0.76 (0.72-0.80) 0.76 (0.73-0.80) 0.43 
 
 
